PURPOSE: Cisplatin has shown a high tumor response rate among head and neck carcinomas, and the tumor response is related to the cisplatin dosage. The purpose of this study was to evaluate the efficacy and toxicity of selective intraarterial chemoradiation therapy for oropharyngeal carcinomas with high-dose cisplatin. MATERIALS AND METHODS: This retrospective study consisted of 21 patients with oropharyngeal carcinoma, stages II-IVB, in whom intraarterial chemoradiation therapy was performed between 2000 and 2008. All patients were given two courses of selective intraarterial infusions of cisplatin (300 mg/m(2)), systemic chemotherapy with 5-fluorouracil, and simultaneous radiation therapy (58-61 Gy/30 fractions), with a 1-week rest period. RESULTS: The 2-year overall survival rate of the 15 patients who completed the therapeutic regimen was 71.3%. The 2-year locoregional control rate and disease-free survival rate were 95.0% and 67.7%, respectively. CONCLUSION: Selective intraarterial high-dose cisplatin chemotherapy with concomitant radiation therapy shows results similar to those of original methods in terms of survival and locoregional control with a reduction in the number of procedure times.
PURPOSE:Cisplatin has shown a high tumor response rate among head and neck carcinomas, and the tumor response is related to the cisplatin dosage. The purpose of this study was to evaluate the efficacy and toxicity of selective intraarterial chemoradiation therapy for oropharyngeal carcinomas with high-dose cisplatin. MATERIALS AND METHODS: This retrospective study consisted of 21 patients with oropharyngeal carcinoma, stages II-IVB, in whom intraarterial chemoradiation therapy was performed between 2000 and 2008. All patients were given two courses of selective intraarterial infusions of cisplatin (300 mg/m(2)), systemic chemotherapy with 5-fluorouracil, and simultaneous radiation therapy (58-61 Gy/30 fractions), with a 1-week rest period. RESULTS: The 2-year overall survival rate of the 15 patients who completed the therapeutic regimen was 71.3%. The 2-year locoregional control rate and disease-free survival rate were 95.0% and 67.7%, respectively. CONCLUSION: Selective intraarterial high-dose cisplatin chemotherapy with concomitant radiation therapy shows results similar to those of original methods in terms of survival and locoregional control with a reduction in the number of procedure times.
Authors: G Calais; M Alfonsi; E Bardet; C Sire; T Germain; P Bergerot; B Rhein; J Tortochaux; P Oudinot; P Bertrand Journal: J Natl Cancer Inst Date: 1999-12-15 Impact factor: 13.506
Authors: K T Robbins; P Kumar; W F Regine; F S Wong; A B Weir; P Flick; L E Kun; R Palmer; T Murry; J Fontanesi; R Ferguson; R Thomas; W Hartsell; C U Paig; G Salazar; L Norfleet; C B Hanchett; V Harrington; H B Niell Journal: Int J Radiat Oncol Biol Phys Date: 1997-05-01 Impact factor: 7.038
Authors: D J Adelstein; V M Sharan; A S Earle; A C Shah; C Vlastou; C D Haria; S G Carter; C Damm; J D Hines Journal: Am J Clin Oncol Date: 1990-10 Impact factor: 2.339
Authors: K T Robbins; J Fontanesi; F S Wong; D Vicario; S Seagren; P Kumar; R Weisman; P Pellitteri; J R Thomas; P Flick; R Palmer; A Weir; C Kerber; T Murry; R Ferguson; G Los; L Orloff; S B Howell Journal: Arch Otolaryngol Head Neck Surg Date: 1996-08
Authors: K T Robbins; P Kumar; F S Wong; W F Hartsell; P Flick; R Palmer; A B Weir; H B Neill; T Murry; R Ferguson; C Hanchett; F Vieira; A Bush; S B Howell Journal: Head Neck Date: 2000-10 Impact factor: 3.147
Authors: A K Murthy; S G Taylor; J Showel; D D Caldarelli; J C Hutchinson; L D Holinger; T R Witt; S Hoover Journal: Int J Radiat Oncol Biol Phys Date: 1987-12 Impact factor: 7.038
Authors: K T Robbins; D Vicario; S Seagren; R Weisman; P Pellitteri; C Kerber; L Orloff; G Los; S B Howell Journal: Am J Surg Date: 1994-11 Impact factor: 2.565
Authors: Y Korogi; T Hirai; R Nishimura; S Hamatake; Y Sakamoto; R Murakami; Y Baba; A Arakawa; M Takahashi; Y Uji Journal: AJR Am J Roentgenol Date: 1995-11 Impact factor: 3.959
Authors: A A Hart; S Mak-Kregar; F J Hilgers; P C Levendag; J J Manni; H A Spoelstra; I A Bruaset; B F van der Laan; A A Annyas; J M van der Beek Journal: Cancer Date: 1995-06-01 Impact factor: 6.860